
ALCEDIAG

A FOR HEALTH

FOR IMMEDIATE RELEASE

ALCEDIAG appoints Aurore Gérigné as *Chief Executive Officer* to drive the company's global expansion

Alexandra Prioux continues as President, ensuring strategic continuity as Alcediag enters its next phase of international growth

PARIS, MONTPELLIER, FRANCE – March 10th, 2026 – Alcediag, a company developing diagnostic solutions in precision psychiatry, today announced the appointment of Aurore Gérigné as Chief Executive Officer. Alexandra Prioux, who has led the company through key stages of its development, will continue to guide Alcediag's strategic direction in her role as President.

This leadership evolution marks a new stage in Alcediag's development as the company accelerates the international deployment of its diagnostic solutions and expands its precision psychiatry platform. The transition strengthens the company's governance as it moves from technological and clinical validation toward scaled commercialization.

Over the past few years, Alcediag has brought its diagnostic test **EDIT-B** into clinical practice in several European countries. The test is now available to psychiatrists and their patients through partnerships in selected countries including France and Switzerland. Building on this foundation, the company now aims to accelerate its international deployment and expand access to its precision psychiatry solutions in additional European markets and worldwide.

EDIT-B is the world's first blood test designed to differentiate depression and bipolar disorder. The test, utilizing RNA editing-based biomarkers, is CE-marked and clinically validated. Alcediag positions EDIT-B as the first step in a broader portfolio of diagnostic solutions aimed at improving clinical decision-making in psychiatry.

As CEO, Aurore Gérigné will focus on scaling the company's operations, accelerating international commercialization and structuring Alcediag's global growth strategy. This will include bringing EDIT-B to new countries in and outside EU and building strategic partnerships with leading diagnostic, pharmaceutical and healthcare players in Europe and globally, to support the broad clinical adoption of Alcediag's precision psychiatry solutions.

Aurore Gérigné brings extensive experience in pharmaceutical industry, with a strong track record in product launches and international market expansion. She has also worked on the development and commercialization of innovative and complex healthcare products. Her deep knowledge of the central nervous system (CNS) and

ALCEDIAG



mental health sectors combined with an entrepreneurship mindset, will support Alcediag's ambition to expand its leadership in precision psychiatry diagnostics.

“Alcediag is committed to advancing precision psychiatry and bringing innovative solutions for patients and healthcare professionals, starting with our first test EDIT-B.” said Alexandra Prioux, President of Alcediag. **“I am convinced that Aurore’s leadership and experience are a key asset to bring that vision to life and to accelerate the deployment of our solutions.”**

“I am thrilled to join Alcediag to lead this innovative diagnostics company focusing on mental health”, said Aurore Gérigné, CEO of Alcediag. **“I look forward to working alongside talented teams to make EDIT-B a true success story for Alcediag. Precision psychiatry diagnostics represent an important step toward the future of healthcare, and I strongly believe in the potential of these innovations to support clinicians in diagnosing mental health disorders and improving patient care.”**

Alcediag's continued growth is supported by the Alcen Group, which remains committed to investing in Alcediag's scientific and industrial development.

About ALCEDIAG

Alcediag is a diagnostics company dedicated to advancing mental health care through precision psychiatry. The company develops and commercializes innovative in vitro diagnostic tests powered by molecular biology and artificial intelligence. Its proprietary platform leverages RNA editing biomarkers to bring objective, science-based tools into clinical psychiatric practice, supporting earlier and more accurate diagnosis of mental health disorders.

For more information:

www.alcediag.com

Contact

contact@alcediag-alcen.com